INT178029

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.76
First Reported 2004
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 25
Total Number 27
Disease Relevance 14.98
Pain Relevance 1.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (Epo) extracellular region (Epo)
Anatomy Link Frequency
fat 2
neurons 2
CFU-E 2
adult kidney 1
brain 1
Epo (Mus musculus)
Pain Link Frequency Relevance Heat
cytokine 42 100.00 Very High Very High Very High
nMDA receptor 6 92.80 High High
Analgesic 3 89.04 High High
dexamethasone 2 86.72 High High
Central nervous system 3 86.32 High High
Inflammation 45 81.20 Quite High
tetrodotoxin 12 78.16 Quite High
Inflammatory response 42 74.72 Quite High
cva 21 72.40 Quite High
metalloproteinase 11 67.48 Quite High
Disease Link Frequency Relevance Heat
Erythrocytosis 213 100.00 Very High Very High Very High
Neurological Disease 2 99.76 Very High Very High Very High
Motor Neuron Diseases 396 99.40 Very High Very High Very High
Apoptosis 149 98.92 Very High Very High Very High
Targeted Disruption 100 98.36 Very High Very High Very High
Anaemia 104 98.00 Very High Very High Very High
Myelodysplastic Syndromes 374 97.84 Very High Very High Very High
Hematological Disease 43 97.00 Very High Very High Very High
Cognitive Disorder 112 95.84 Very High Very High Very High
Disease 262 95.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The production of EPO by means of recombinant techniques and its availability in various competent recombinant forms, make EPO an economical drug, conferring it as a potential candidate for enhancing fat transplantation without increasing considerably the cost of the procedure.
Gene_expression (production) of EPO in fat
1) Confidence 0.76 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 1.14 Pain Relevance 0.07
Erythropoietin (Epo) was first identified as an haematopoietic growth factor produced in the kidneys, and recombinant human Epo (rhEpo) is widely used to treat anaemia [7].
Gene_expression (produced) of Epo associated with anaemia
2) Confidence 0.76 Published 2008 Journal Malar J Section Body Doc Link PMC2257967 Disease Relevance 1.28 Pain Relevance 0.15
The observation that Epo and its receptor are expressed in practically all brain cells expanded the biological role of Epo beyond haematopoiesis (reviewed in [9,10]).
Gene_expression (expressed) of Epo in brain associated with hematological disease
3) Confidence 0.76 Published 2008 Journal Malar J Section Body Doc Link PMC2257967 Disease Relevance 0.92 Pain Relevance 0.12
Therefore, erythropoietin (Epo) gene transfer appears to be a promising alternative for severe anaemia treatment since it requires less frequent treatment repeat and may allow sustained Epo secretion and constant patient coverage.
Gene_expression (transfer) of Epo associated with anaemia
4) Confidence 0.76 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.60 Pain Relevance 0
Epo gene transfer has already been tested on normal animals and on anaemia animal models such as ?
Gene_expression (transfer) of Epo associated with anaemia
5) Confidence 0.76 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.63 Pain Relevance 0
Therefore, erythropoietin (Epo) gene transfer appears to be a promising alternative for severe anaemia treatment since it requires less frequent treatment repeat and may allow sustained Epo secretion and constant patient coverage.
Gene_expression (transfer) of erythropoietin associated with anaemia
6) Confidence 0.76 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.60 Pain Relevance 0
Furthermore, we may hypothesise that this administration schedule which leads to low Epo endogenous production, may limit humoral response which has been clearly correlated to transgene expression level [26].
Gene_expression (production) of Epo
7) Confidence 0.76 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.19 Pain Relevance 0.06
Additional experiments, such as administering low-dose murine Epo chronically, or generating a mouse expressing low levels of Epo transgenically, would further address whether SPL has a similar effect of a similar time frame in secondary (Epo) versus mutant-driven (V617F) polycythemia.
Gene_expression (expressing) of Epo associated with erythrocytosis
8) Confidence 0.68 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2749451 Disease Relevance 1.05 Pain Relevance 0
There were no morphological differences detectable upon treatment, and sizes of somata as estimated by measurement of whole cell capacitance were comparable between EPO-treated and control neurons (control neurons: 49.61 ± 2.75pF, N = 54; EPO neurons: 46.0 ± 2.73pF, N = 49; P = 0.355).
Gene_expression (neurons) of EPO in neurons
9) Confidence 0.67 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0 Pain Relevance 0
Reduction of synaptic vesicle priming and transmitter release in the EPO pre-treated neurons
Gene_expression (pre) of EPO in neurons
10) Confidence 0.67 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0 Pain Relevance 0
This transformation activity may depend upon co-expression of a single-chain type I cytokine receptor, such as Epo receptor, G-CSF receptor, or thrombopoietin receptor [36].
Gene_expression (expression) of Epo associated with cytokine
11) Confidence 0.66 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.85 Pain Relevance 0.16
Briefly, 100 µl PBS or 200 ng VEGF/100 µl PBS were injected every three days for 18 days in an identical manner to that of the PBS- or EPO-treated mice in the first experiment.
Gene_expression (injected) of EPO
12) Confidence 0.66 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0 Pain Relevance 0.09
Indeed, the increased VEGFR-2 expression in the EPO-treated fat grafts that was observed in our study implies that EPO-induced endogenous VEGF secretion in the fat grafts might be more effective than exogenous VEGF administration.
Gene_expression (expression) of EPO in fat
13) Confidence 0.66 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2981551 Disease Relevance 0.41 Pain Relevance 0.03
However, rhEpo injections remain an expensive treatment which requires frequent delivery injection repeats and which can lead to anti-Epo antibodies production by the patient [1].
Gene_expression (production) of Epo
14) Confidence 0.66 Published 2008 Journal Genet Vaccines Ther Section Body Doc Link PMC2276190 Disease Relevance 0.59 Pain Relevance 0
To examine the changes in synaptic NMDA/AMPA ratios in presence and absence of EPO, the NMDA components relative to the AMPA component were measured.
Neg (absence) Gene_expression (absence) of EPO
15) Confidence 0.60 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0 Pain Relevance 0.27
However, the finding that EPO and its receptor (EPOR) are expressed in the brain [6,7] (for review see also [1,3,8-11]) led to the notion that EPO exerts direct, hematopoiesis-independent effects on the nervous system.
Gene_expression (expressed) of EPO in nervous system associated with hematological disease
16) Confidence 0.60 Published 2008 Journal BMC Biol Section Body Doc Link PMC2562991 Disease Relevance 0.80 Pain Relevance 0.03
AsialoEPO was synthesized from EPO exactly as described [28].
Gene_expression (synthesized) of AsialoEPO
17) Confidence 0.60 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC434499 Disease Relevance 0.39 Pain Relevance 0
AsialoEPO was synthesized from EPO exactly as described [28].
Gene_expression (synthesized) of EPO
18) Confidence 0.60 Published 2004 Journal BMC Neurosci Section Body Doc Link PMC434499 Disease Relevance 0.39 Pain Relevance 0
Thus, a stronger erythropoietic drive has the potential to explain the presence (Epo) or absence (V617F) of polycythemia following SPL in these 2 models.
Gene_expression (following) of Epo associated with erythrocytosis
19) Confidence 0.59 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2749451 Disease Relevance 0.85 Pain Relevance 0
CFU-E and Epo assays
Gene_expression (CFU-E) of Epo in CFU-E
20) Confidence 0.58 Published 2006 Journal PLoS ONE Section Body Doc Link PMC1762384 Disease Relevance 0.27 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox